Premium
Dietary flavonoid fisetin for cancer prevention and treatment
Author(s) -
Lall Rahul K.,
Adhami Vaqar Mustafa,
Mukhtar Hasan
Publication year - 2016
Publication title -
molecular nutrition and food research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.495
H-Index - 131
eISSN - 1613-4133
pISSN - 1613-4125
DOI - 10.1002/mnfr.201600025
Subject(s) - fisetin , cancer , cancer prevention , pharmacology , medicine , metastasis , flavonoid , carcinogenesis , angiogenesis , mechanism (biology) , cancer cell , cancer research , clinical trial , bioinformatics , biology , biochemistry , philosophy , epistemology , antioxidant
Cancer remains a major public health concern and a significant cause of death worldwide. Identification of bioactive molecules that have the potential to inhibit carcinogenesis continues to garner interest among the scientific community. In particular, flavonoids from dietary sources are the most sought after because of their safety, cost‐effectiveness, and feasibility of oral administration. Emerging data have provided newer insights into understanding the molecular mechanisms that are essential to identify novel mechanism‐based strategies for cancer prevention and treatment. Dietary flavonoid fisetin (3,3′,4′,7‐tetrahydroxyflavone) found in many fruits and vegetables has been shown in preclinical studies to inhibit cancer growth through alteration of cell cycle, inducing apoptosis, angiogenesis, invasion, and metastasis without causing any toxicity to normal cells. Although data from in‐vitro and in‐vivo studies look convincing, well‐designed clinical trials in humans are needed to conclusively determine the efficacy across various cancers. This review highlights the chemopreventive and therapeutic effects, molecular targets, and mechanisms that contribute to the observed anticancer activity of fisetin against various cancers.